Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ESRRG | P62508 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14832628 | 0.90 | MAOB (0.43) | GFERCYP19A1NPC1RAB9AMAOB | |
| SCHEMBL24197444 | 0.89 | TAAR1 (0.44) | MAOBALDH1A1TDP1LOXL2SMN1; SMN2 | |
| SCHEMBL22011318 | 0.87 | NPC1 (0.46) | CYP19A1NPC1RAB9AMAOBMAOA | |
| SCHEMBL2696466 | 0.84 | CYP1A2 (0.41) | NPC1RAB9AMAOBMAOADUT | |
| SCHEMBL2142371 | 0.82 | PPARA (0.42) | DUTALDH1A1TSHRTDP1MAPT | |
| SCHEMBL2821530 | 0.82 | ESR1 (0.45) | NPC1RAB9AALDH1A1CYP3A4TDP1 | |
| SCHEMBL1245973 | 0.82 | ELOVL1 (0.41) | MAOBDUT | |
| SCHEMBL21178368 | 0.82 | DUT (0.36) | DUT | |
| SCHEMBL5871377 | 0.82 | MEN1 (0.42) | DUTTDP1 | |
| SCHEMBL26807117 | 0.82 | KCNH2 (0.42) | DUTESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC (US) | 2025-10-02 | — | — | US | disclosed |
| CN-120092003-A | CDK protein degrading agents, pharmaceutical compositions and therapeutic uses | 拜欧斯瑞克斯公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-02 | — | — | US | disclosed |
| EP-4480482-A2 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | AbbVie Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | ABBVIE INC. (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024259216-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4249073-B1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024117789-A1 | PLK1 DEGRADATION INDUCING COMPOUNDS WITH INCREASED RIGIDITY | UPPTHERA, INC. (KR) | 2024-06-06 | — | — | WO | disclosed |
| US-20240109877-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC. | 2024-04-04 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| WO-2015200709-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| EP-2364983-B1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2364983-A2 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Jeil Pharmaceutical Co., Ltd. (KR) | 2011-09-14 | — | — | EP | disclosed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | disclosed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| US-5998432-A | SEXUAL DISORDERS | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5985892-A | USEFUL FOR THE TREATMENT OF A VARIETY OF SEX-HORMONE RELATED AND OTHER CONDITIONS IN BOTH MEN AND WOMEN; PREVENTING PREGNANCY; TREATING LUPUS ERYTHEMATOSIS, IRRITABLE BOWEL SYNDROME, PREMENSTRUAL SYNDROME, HIRSUTISM, SHORT STATURE OR A | MERCK & CO., LTD. (US) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | BTK, TYMP, LYN | GFER 2901/4885CYP19A1 1516/4885NPC1 4514/4885 |
| US-20240109877-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | BTK, TYMP, LYN | GFER 2901/4885CYP19A1 1516/4885NPC1 4514/4885 |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PARP1, PARP15, PARP11 | GFER 3754/4885CYP19A1 707/4885NPC1 2588/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | GFER 3125/4885CYP19A1 3515/4885NPC1 3666/4885 |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | GFER 380/4885CYP19A1 840/4885NPC1 64/4885 |
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | EGFR, ERBB2, ERBB4 | GFER 305/4885CYP19A1 669/4885NPC1 4335/4885 |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | BTK, TYMP, LYN | GFER 2901/4885CYP19A1 1516/4885NPC1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.